Comparison of Propofol Alone and in Combination with Ketamine Or
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Effect of Intranasal Ketamine Vs Fentanyl on Pain
1 PROTOCOL SYNOPSIS 2 STUDY TITLE: 3 Pain Reduction with Intranasal Medications for Extremity Injuries (PRIME): A Randomized Clinical 4 Noninferiority Trial of Intranasal Ketamine vs. Fentanyl 5 6 PROTOCOL TITLE 7 Pain Reduction with Intranasal Medications for Extremity injuries (PRIME) 8 9 PRINCIPAL INVESTIGATOR: 10 Theresa M. Frey, MD 11 Assistant Professor Clinical Pediatrics 12 Division of Pediatric Emergency Medicine 13 Cincinnati Children’s Hospital Medical Center 14 513-636-7966 15 [email protected] 16 17 CO-INVESTIGATORS: 18 Matthew R. Mittiga, MD 19 Todd A. Florin, MD, MSCE 20 Michelle C. Caruso, PharmD, BCPS 21 Nanhua Zhang, PhD 22 Yin Zhang, MS 23 24 I. ABSTRACT 25 26 Introduction: Inadequate pain control in the emergency department, particularly in the pediatric 27 population, is a major health concern. The intranasal route of medication administration is gaining 28 popularity secondary to its rapid onset of action, minimal discomfort for the patient and relative 29 simplicity. When pediatric patients present with moderate to severe pain from traumatic injuries, 30 opioids are currently the most frequently used class of analgesia, but they may not always be the best 31 option for numerous reasons. Sub-dissociative dosing of ketamine has been shown to be an effective 32 alternative to opioids in providing adequate pain relief. 33 34 Objectives: The objectives of this study are to 1) determine if intranasal ketamine is non-inferior to 35 intranasal fentanyl in reduction of pain in children presenting with extremity injuries and 2) define and 36 compare the level of sedation and respiratory side effect profile associated with intranasal ketamine and 37 fentanyl. -
Biased Versus Partial Agonism in the Search for Safer Opioid Analgesics
molecules Review Biased versus Partial Agonism in the Search for Safer Opioid Analgesics Joaquim Azevedo Neto 1 , Anna Costanzini 2 , Roberto De Giorgio 2 , David G. Lambert 3 , Chiara Ruzza 1,4,* and Girolamo Calò 1 1 Department of Biomedical and Specialty Surgical Sciences, Section of Pharmacology, University of Ferrara, 44121 Ferrara, Italy; [email protected] (J.A.N.); [email protected] (G.C.) 2 Department of Morphology, Surgery, Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; [email protected] (A.C.); [email protected] (R.D.G.) 3 Department of Cardiovascular Sciences, Anesthesia, Critical Care and Pain Management, University of Leicester, Leicester LE1 7RH, UK; [email protected] 4 Technopole of Ferrara, LTTA Laboratory for Advanced Therapies, 44122 Ferrara, Italy * Correspondence: [email protected] Academic Editor: Helmut Schmidhammer Received: 23 July 2020; Accepted: 23 August 2020; Published: 25 August 2020 Abstract: Opioids such as morphine—acting at the mu opioid receptor—are the mainstay for treatment of moderate to severe pain and have good efficacy in these indications. However, these drugs produce a plethora of unwanted adverse effects including respiratory depression, constipation, immune suppression and with prolonged treatment, tolerance, dependence and abuse liability. Studies in β-arrestin 2 gene knockout (βarr2( / )) animals indicate that morphine analgesia is potentiated − − while side effects are reduced, suggesting that drugs biased away from arrestin may manifest with a reduced-side-effect profile. However, there is controversy in this area with improvement of morphine-induced constipation and reduced respiratory effects in βarr2( / ) mice. Moreover, − − studies performed with mice genetically engineered with G-protein-biased mu receptors suggested increased sensitivity of these animals to both analgesic actions and side effects of opioid drugs. -
Statement on Safe Use of Propofol 2019
Statement on Safe Use of Propofol Committee of Origin: Ambulatory Surgical Care (Approved by the ASA House of Delegates on October 27, 2004, and amended on October 23, 2019) Because sedation is a continuum, it is not always possible to predict how an individual patient will respond. Due to the potential for rapid, profound changes in sedative/anesthetic depth and the lack of antagonist medications, agents such as propofol require special attention. Even if moderate sedation is intended, patients receiving propofol should receive care consistent with that required for deep sedation. The Society believes that the involvement of an anesthesiologist in the care of every patient undergoing anesthesia is optimal. However, when this is not possible, non-anesthesia personnel who administer propofol should be qualified to rescue* patients whose level of sedation becomes deeper than initially intended and who enter, if briefly, a state of general anesthesia.** • The physician responsible for the use of sedation/anesthesia should have the education and training to manage the potential medical complications of sedation/anesthesia. The physician should be proficient in airway management, have advanced life support skills appropriate for the patient population, and understand the pharmacology of the drugs used. The physician should be physically present throughout the sedation and remain immediately available until the patient is medically discharged from the post procedure recovery area. • The practitioner administering propofol for sedation/anesthesia should, at a minimum, have the education and training to identify and manage the airway and cardiovascular changes which occur in a patient who enters a state of general anesthesia, as well as the ability to assist in the management of complications. -
Intravenous Sedation and Preparing for Your Procedure
Oral and Maxillofacial Surgery Intravenous sedation and preparing for your procedure Information for patients Please ensure that you read this leaflet before you come to hospital for your operation What is sedation? Sedation is a way of using drugs (sedatives) to make you feel relaxed and sleepy during your procedure. We will give you your sedatives through an injection into a vein. Sedation is not a general anaesthetic and you will not be unconscious. You may not remember much of what happens during the procedure and directly afterwards. This is quite normal. Local anaesthetic will be given once you have been sedated. Do not drive, operate machinery or sign important documents for at least 24 hours after your procedure. You must make sure that you have a responsible adult with you who can stay in the department for a couple of hours and take you home by car or taxi. Someone must also stay with you for at least 24 hours after your procedure. Your procedure will be cancelled if you do not bring someone with you who can do this. Preparation for your procedure and what to bring with you • Patients having a procedure under sedation must follow the current fasting guidelines for general anaesthesia. You must not eat or drink for 6 hours before your procedure but you may have water up to 2 hours before. If you do eat or drink after these times your surgery will be cancelled. • Avoid alcohol for 24 hours before your procedure. • Bring with you a list of any medication or drugs you are taking. -
Opioid Receptorsreceptors
OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors. -
Moderate Sedation Study Guide 11-17-10
PROCEDURE RELATED SEDATION Outline I Introduction II Definitions: The 5 Levels of Sedation and Anesthesia III Emergency Procedures, Critical Care Areas and Policy Exclusions IV The Pre-Sedation Assessment V NPO: The Timing of Eating and Drinking before Sedation VI Review of Some Agents Used for Sedation VII Orders for Procedure Related Sedation VIII Environmental Requirements and Monitoring During Sedation IX Post-Procedure Monitoring and the PAR Score X Discharge Criteria and Concluding Post-Procedure Monitoring 1 PROCEDURE RELATED SEDATION Lance Brown, MD, MPH I. Introduction The purpose of this tutorial is to familiarize the reader with the Loma Linda University Medical Center Policy M-86 for Procedure Related Sedation. Procedure related sedation is used to make necessary medical procedures as comfortable as possible for patients and to facilitate the performance of necessary medical procedures by health care providers (typically physicians). It is important for health care providers performing procedure related sedation to be familiar with the pharmacologic characteristics of the agents being used, to understand the risk factors for complications related to procedure related sedation, and to individually plan the sedation for each patient. Each health care practitioner privileged to provide procedure related sedation takes responsibility for both the comfort and safety of the patients in their care. II. Definitions At Loma Linda University Medical Center, we have defined five distinct levels of sedation and anesthesia. Familiarity with the definitions of these levels of sedation is important for safely providing procedure related sedation and for complying with the policy of the Medical Center. It must be recognized, however, that sedation occurs along a continuum and that individual patients may have different degrees of sedation for a given dose and route of medication. -
Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A. -
Fentanyl Infographic 24X36
FENTANYL WHAT IS IT? Fentanyl can be found in prescription form, introduced to the medical community in the 1960s Fentanyl analogues are now being Fentanyl is a potent synthetic and prescribed to relieve severe pain post-surgery created in clandestine laboratories to opioid analgesic, 50 to 100x or during end-of-life care . In its prescription form, be sold and used illegally. In it's non- more powerful than fentanyl is sold under the brand names Actiq®, prescription form, fentanyl is found in morphine. Duragesic®, and Sublimaze®. When prescribed by a powder form, spiked on blotter paper; physician, fentanyl is often administered via mixed with heroin; or as tablets that injection, transdermal patch, or in lozenges. attempt to mimic other opioids. Effects: Like other opioids, Fentanyl binds to Through Fentanyl's effects on the Euphoria, relaxation, drowsiness, opioid receptors in the reward centers opioid receptors in the brain stem nausea, confusion, constipation, of the brain, increasing dopamine however, it can inhibit normal sedation, tolerance, addiction, levels to cause a surge in endorphins breathing, causing breathing to stop respiratory depression and arrest, and feelings of pleasure. altogether, leading to death. unconsciousness, coma, and death. WHY DOES IT MATTER? 540% While the fast-acting nature of the effects of fentanyl may create a more powerful and immediate euphoria, these increase in fentanyl effects wear off faster, leading to the more immediate return overdose deaths of cravings and discomfort. since 2016 (CDC) With a high profit margin, Fentanyl is often mixed into heroin or is made to mimic the In talking about Fentanyl, you may hear about appearance of other opioids. -
Marijuana Is Cannabis with Tetrahydrocannabinol (THC). Strains Without THC Are Often Classified As Hemp
“COMBATING 21ST CENTURY DRUGS WITH SUCCESSFUL OUTCOMES” William L. Parker CEO American Court & Drug Testing Services [email protected] THE SUPREME COURT OF OHIO SPECIALIZED DOCKETS CONFERENCE Fentanyl and its correlation to fatal overdoses Thursday, October 11, 2018 in Ohio, a relatively new threat called Flakka, 11:45 a.m. – 1:00 p.m. CBD oils and how to incorporate these drugs into an effective drug testing program. Friday, October 12, 2018 1:15 p.m. – 2:30 p.m. FENTANYL Fentanyl is an opioid which is used as a pain medication and together with other medications for anesthesia or to relieve pain in terminally ill cancer patients. Fentanyl is available in a number of forms including by injection, as a skin patch, and to be absorbed through the tissues inside the mouth. Fentanyl about 75 times stronger than morphine for a given amount. Some fentanyl analogues may be as much as 10,000 times stronger than morphine. FENTANYL Fentanyl was created in 1959 by Paul Jannsen, founder of Jannsen Pharmaceutical and first used medically as anesthetic in 1968. Fentanyl patches were first introduced in the mid 1990’s as a pain management treatment for Opiate-tolerate patients. Fentanyl was first used for pain management in cancer patients in 2009. FENTANYL Recreational use of Fentanyl started in the mid 1970’s among medical professionals. The use of Fentanyl – especially from the illegal manufacturing of the drug has increased exponentially over the past three years. Since 2012 Fentanyl related overdoses and deaths have produced staggering statistics in almost every state in the U.S. -
Post-Intubation Analgesia and Sedation
POST-INTUBATION ANALGESIA AND SEDATION August 2012 J Pelletier Intubated patients experience pain and anxiety Mechanical ventilation, endotracheal tube Blood draws, positioning, suctioning Surgical procedures, dressing changes Awareness during neuromuscular blockade Invasive catheters Loss of control Unrelieved pain and anxiety cause adverse effects Self-injury and removal of life-sustaining devices Increased endogenous catecholamines Sleep deprivation, anxiety, and delirium Impaired post-ICU psychological recovery Emotional and posttraumatic effects Ventilator dysynchrony Immunosuppression Treating pain and anxiety improves outcomes Use of pain and sedation scales in critically ill patients allows: precise dosing reduced medication side effects reduced ICU and hospital length of stay shorter duration of mechanical ventilation Analgesics should be provided first, then anxiolysis If you were intubated, how much lorazepam or midazolam, and fentanyl would you want per hour? Intubated ED patients receive inadequate analgesia and sedation Retrospective study, tertiary ED 50% received no analgesia, 30% received no anxiolytic Of patients receiving postintubation vecuronium, 96% received either no or inadequate anxiolysis or analgesia Overall, 3 of 4 patients received no or inadequate analgesia and an equivalent number received no or inadequate anxiolysis Bonomo 2007 Analgesia: opioids Bind CNS and peripheral tissue receptors Mu-1 receptors: analgesia Mu-2 receptors: respiratory depression, vomiting, constipation, and -
Patient-Controlled Transdermal Fentanyl Hydrochloride Vs Intravenous Morphine Pump for Postoperative Pain a Randomized Controlled Trial
ORIGINAL CONTRIBUTION Patient-Controlled Transdermal Fentanyl Hydrochloride vs Intravenous Morphine Pump for Postoperative Pain A Randomized Controlled Trial Eugene R. Viscusi, MD Context Patient-controlled analgesia (PCA) with morphine is commonly used to pro- Lowell Reynolds, MD vide acute postoperative pain control after major surgery. The fentanyl hydrochloride Frances Chung, MD patient-controlled transdermal system eliminates the need for venous access and com- plicated programming of pumps. Linda E. Atkinson, PhD Objective To assess the efficacy and safety of an investigational patient-controlled Sarita Khanna, PhD iontophoretic transdermal system using fentanyl hydrochloride compared with a stan- dard intravenous morphine patient-controlled pump. ATIENT-CONTROLLED ANALGE- Design, Setting, and Patients Prospective randomized controlled parallel-group sia (PCA) allows the patient to trial conducted between September 2000 and March 2001 at 33 North American hos- self-administer small doses of pitals, enrolling 636 adult patients who had just undergone major surgery. opioids, such as fentanyl, mor- Interventions In surgical recovery rooms, patients were randomly assigned to in- Pphine, hydromorphone, or meperi- travenous morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h) by a patient- dine, as needed to manage pain. A key controlled analgesia pump (n=320) or iontophoretic fentanyl hydrochloride (40-µg principle of PCA use is that it is initi- infusion over 10 minutes) by a patient-controlled transdermal system (n=316). Supple- ated after titration to patient comfort mental analgesia (morphine or fentanyl intravenous boluses) was administered as needed with loading doses of intravenous (IV) before and for the first 3 hours after activation of the PCA treatments. -
The Inhibition of Enkephalin Catabolism by Dual Enkephalinase Inhibitor: a Novel Possible Therapeutic Approach for Opioid Use Disorders
Alvarez-Perez Beltran (Orcid ID: 0000-0001-8033-3136) Maldonado Rafael (Orcid ID: 0000-0002-4359-8773) THE INHIBITION OF ENKEPHALIN CATABOLISM BY DUAL ENKEPHALINASE INHIBITOR: A NOVEL POSSIBLE THERAPEUTIC APPROACH FOR OPIOID USE DISORDERS ALVAREZ-PEREZ Beltran1*, PORAS Hervé 2*, MALDONADO Rafael1 1 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, c/Dr Aiguader 88, 08003 Barcelona, Spain, 2 Pharmaleads, Paris BioPark, 11 Rue Watt, 75013 Paris, France *Both authors participated equally to the manuscript Correspondence: Rafael Maldonado, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), c/Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: [email protected] ABSTRACT Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual Enkephalinase Inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggest that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.